CAS No. |
161715-20-4 |
中文名称 |
(1R,5S,6S)-2-[((1-(4,5-二氢噻唑-2-基)氮杂环丁烷-3-基)硫基)]-6-[(R)-1-羟基乙基]-1-甲基-6-(4-硝基苄基)-7-氧代双环[3.2.0]庚-2-烯-3-羧酸 |
英文名称 |
(1R,5S,6S)-2-((1-(4,5-Dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-1-methyl-6-(4-nitrobenzyl)-7-oxobicyclo[3.2.0]hept-2-ene-3-carboxylic acid |
别名 |
4-Nitrobenzyl(1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-Methyl-2-[1-(1,3-thiazolin-2-yl)azetidin -3-yl]thio-1-carbapen-2-eM-3-carboxylate;(4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (4-nitrophenyl)methyl ester;Tebipenem Impurity 4;(4R,5S,6S)-4-nitrobenzyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;(1R,5S,6S)-2-((1-(4,5-Dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-1-methyl-;TebipeneM Condensation CoMpound;(1R,5S,6S)-2-((1-(4,5-Dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-1-methyl-6-(4-nitrobenzyl)-7-oxobicyclo[3.2.0]hept-2-ene-3-carboxylic acid;1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, (4R,5S,6S)- |
标准英文名 |
(1R,5S,6S)-2-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-1-methyl-6-(4-nitrobenzyl)-7-oxobicyclo[3.2.0]hept-2-ene-3-carboxylic acid |
分子式 |
C24H27N3O6S2 |
分子量 |
517.63
|
精确分子量 |
517.13
|
SMILES |
O=C(C(C[C@@]1([H])[C@]2([C@H](O)C)CC3=CC=C([N+]([O-])=O)C=C3)=C(SC4CN(C5=NCCS5)C4)[C@@]1(C)C2=O)O |
标准SMILES |
C[C@]12[C@@H](CC(=C1SC1CN(C1)C1=NCCS1)C(O)=O)[C@@](CC1C=CC(=CC=1)[N+]([O-])=O)([C@@H](C)O)C2=O |
用途 |
Tebipenem is a novel, orally administered carbapenem antibiotic used for the treatment of pediatric patients with ear, nose, throat, and upper respiratory tract infections, including persistent otitis media and bacterial pneumonia. It exhibits potent activity against a broad spectrum of bacteria, including Gram-positive, Gram-negative, and anaerobic organisms, as well as resistant strains such as penicillin-resistant *Streptococcus pneumoniae* (PRSP), macrolide-resistant *S. pneumoniae* (MRSP), and ampicillin-resistant *Haemophilus influenzae*. As the first oral carbapenem approved for clinical use, it is specifically developed for children and demonstrates superior oral bioavailability compared to other marketed β-lactam antibiotics. Its mechanism of action involves inhibition of bacterial cell wall synthesis through strong binding to penicillin-binding proteins (PBPs), particularly showing higher affinity for PBPs of PRSP than other β-lactams. Tebipenem is indicated only when other commonly used antibacterial agents are not expected to be effective. |
InChIKey |
VQXNMVCVJPPTHN-NAVZNGSCSA-N |